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Between 1964 and 1991, vaginal hysterectomy was performed in 60 
patients with clinical stage I endometrial carcinoma, who were not 
considered candidates for the conventional surgical approach. Of these 
patients, 66.7% were obese with a median weight of 235 pounds. Other 
risk factors included hypertension (63%), diabetes mellitus (34%), cardiac 
disease (28%) and pulmonary disease (12%). Operative mortality was 0%. 
The complication rate was 14%, with four patients requiring transfusions 
and four patients developing vaginal cuff cellulitis. Forty per cent of 
patients received adjuvant pre- or postoperative radiation therapy. Crude 
survival at 5 and 10 years was 91.1% and 87.1%, respectively. However, 
only one patient died from disease 6 years after primary treatment. 
Although we consider surgical staging as the standard of care for the 
treatment of endometrial cancer, vaginal hysterectomy has a definite 
place in the management of patients with good prognostic criteria who 
are at high operative risk for the standard surgical approach. 
KEYWORDS: complications, endometrial cancer, risk factors, survival, vaginal 
hysterectomy. 
Vaginal hysterectomy used to be the treatment of 
choice for endometrial carcinoma in Europe (1-3) as 
well as an acceptable treatment option in the USA (4). 
Today, however, the attitude towards the vaginal 
approach has changed dramatically, and surgery 
through the abdominal route is considered the 
standard of care. This is illustrated by the fact that, 
in a recently published textbook, Park et al. ~5) do not 
discuss vaginal hysterectomy as a treatment option for 
patients with endometrial cancer. 
In 1983, Peters et al. (6) reported their experience with 
the use of vaginal hysterectomy in the treatment of 
endometrial carcinoma at the University of Michigan 
Medical Center and at the University of Virginia 
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School of Medicine, USA. At the time of Peters' report, 
staging of endometrial cancer was done clinically, and 
abdominal hysterectomy and bilateral salpingo- 
oophorectomy with or without postoperative 
radiation was considered the treatment of choice for 
endometrial cancer. In 1988, the FIGO adopted 
surgical staging for carcinoma of the endometrium (7), 
and peritoneal cytology as well as pelvic and para- 
aortic lymph node sampling became part of routine 
treatment. Consequently, if vaginal hysterectomy is to 
be considered as an alternative treatment, strict 
selection criteria must be applied, and treatment 
results have to be surveyed critically. 
The following report represents our experience with 
60 patients at the University of Michigan Medical 
Center, USA. It encompasses and updates the 
previously published data. In addition, 24 new 
patients are included in the study. It is the intention 
of the authors to revive the discussion of vaginal 
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hysterectomy as treatment for endometrial  cancer and 
to demonstrate  that it is an acceptable treatment 
alternative for patients who are not candidates for 
s tandard abdominal  surgery. 
Patients and methods 
Through the University of Michigan Tumor  Registry, 
records of all patients were obtained who  had been 
treated by  vaginal hysterectomy for endometrial  
carcinoma between 1 January 1964 and 31 December 
1991. Patients who underwent  vaginal hysterectomy at 
an outside institution and were referred to the 
University of Michigan for further therapy were not 
included. Results from patients treated between 1964 
and 1981 had been reported previously by  Peters et 
al. (6) All charts were reviewed with regards to the 
medical history at the time of presentation, the 
treatment and hospital course as well as visits at the 
Gynecologic Tumor  Clinic. Further follow-up data 
were obtained through the Michigan Tumor  Registry. 
If outside slides were available, they were reviewed by  
a gynecologic pathologist  at the University of 
Michigan. Statistical analysis was performed using 
the SPSSX program. 
Results 
Between 1964 and 1991, vaginal hysterectomy for 
endometrial  cancer was performed on 60 patients. 
One to six patients were treated by  vaginal surgery 
every year. 
The clinical characteristics of the patients are 
summarized in Table 1. The median  age was 59.5 
years. The youngest  patient treated was 27 years old 
and the oldest patient 82 years. The median parity was 
three and the median  weight 235 pounds,  with a range 
of 118-422 pounds.  The majority of patients had 
numerous  medical problems. Hypertension (63%), 
Table 1. Patient characteristics 
Median age 59.5 years (27-82 years) 
Median parity 3 (0-12) 
Median weight 235 pounds (118-422 pounds) 
Additional diagnoses n % 
Hypertension 38 63 
Diabetes meIlitus 20 34 
Cardiac disease 17 28 
Pulmonary disease 7 12 
Symptomatic pelvic 
relaxation 10 17 
diabetes mellitus (34%) and cardiac disease (28%) 
were the most  frequent diagnoses. Furthermore,  
symptomatic  pelvic relaxation was present in 10 
patients (17%). 
As the abdominal  approach was considered the 
s tandard of care for the time frame studied, the 
patients' charts state the specific indications for the 
vaginal surgery. These indications are listed in Table 2. 
Two-thirds of the patients were considered obese and, 
in 31.7% of cases, morbid obesity was the predominant  
determinant  for the vaginal surgery. Frequently, the 
indication was based on the presence of several risk 
factors for abdominal  surgery, including obesity, 
diabetes mellitus and cardiac disease. 
Table 2. Indications for vaginal hysterectomy 
n % 
Obese patients 40 66.7 
Morbid obesity alone 19 31.7 
Diabetes mellitus 7 11.7 
Cardiac disease 5 8.3 
Cardiac disease and diabetes 3 5.0 
Pelvic relaxation 3 5.0 
Sarcoidosis with renal damage 1 1.7 
Recurrent ventral hernia 1 1.7 
Previous anesthesia complication 1 1.7 
Non-obese patients 20 33.3 
Premalignant lesion on D&C 6 10.0 
Pelvic relaxation and unexpected or 
early invasive disease 5 8.3 
Early invasive disease 2 3.3 
Severe cardiac disease 2 3.3 
Diabetes and pelvic relaxation 1 1.7 
Parkinson's and severe cardiac disease 1 1.7 
Liver metastasis from other primary 1 1.7 
Indication not mentioned 2 3.3 
Twenty  patients (33.3%) undergoing vaginal 
hysterectomy for endometrial  cancer were not 
considered overweight.  Thirteen of the 20 patients 
were diagnosed either with a premalignant  lesion, 
such as endometrial  hyperplasia with atypia or early 
invasive disease such as a well-differentiated 
carcinoma developing in an endometrial  polyp but  
without  invasion. In five of these cases, patients were 
asymptomatic and the diagnosis of malignancy was 
established only as an incidental finding after 
hysterectomy and vaginal repair for pelvic relaxation. 
Severe cardiac disease was present in three patients. 
In one patient with liver metastases from colon cancer 
the hysterectomy was also performed vaginally. 
The median operative time was I h and 44 min, with 
a median blood loss of 250 cc (Table 3). Both operative 
time and blood loss were significantly correlated with 
the patients" weight. 
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Table  3. Surgery 
Median operative time* 104 min (50-170 min) 
Median intraoperative blood losst 250 cc (100-1200 cc) 
Additional surgical procedures n % 
Anterior/posterior repair 10 17 
Bilateral salpingo-oophorectomy 7 12 
Unilateral salpingo-oophorectomy 6 10 
Morcellation 4 7 
Schuchardt incision 2 3 
*Correlated with patients' weight: r = 0.56; P = 0.004. 
tCorrelated with patients' weight: r= 0.46; P=0.011. 
An anterior  and  poster ior  repair  was  done  in 10 
cases (17%). Removal  of both  ovaries and  tubes was  
a t t empted  in all patients, but  was  feasible in only 
seven cases for technical reasons. In another  six cases, 
only a unilateral sa lp ingo-oophorec tomy could be 
performed.  Morcellation and the Schuchardt  incision 
were  used in four and two  cases, respectively. 
The complicat ion rate was  low (Table 4). None  of the 
60 hysterectomies had to be  completed abdominal ly.  
In t raopera t ive  bleeding requiring transfusion was  
encountered in four  patients  (7%) and  vaginal  cuff 
cellulitis occurred in four patients. There were  no 
b ladder  or rectal injuries and  no pu lmona ry  
embol izat ion occurred. Operat ive  mortal i ty  was  0%. 
Hospi ta l  s tay was  short, with a med ian  durat ion of 6 
days  and a range of 2 -16  days. 
Table  4. Complications 
n % 
Bleeding requiring transfusion 4 7 
Postoperative infection 4 7 
(vaginal cuff cellulitis) 
Histologic evaluat ion showed  90% of cancers to be 
adenocarc inomas  (Fig. 1). Three of the patients with 
adenocarc inomas  also had  squamous  differentiation 
(5.0%), one had  an adenosquamous  lesion, one a clear 
cell carcinoma and one a carcinosarcoma. The majori ty 
of tumors  were  well differentiated (68%); 18% were 
Carcinosarcoma (I) 
Clear cell (I) 
~quamous differentiation (5) 
Jenosquamous (I) 
Adenococinoma (54) 
Fig. 1. Histologic type. n = 60. 
modera te ly  differentiated; and  7% poorly  differ- 
entiated (Fig. 2). In four instances, pa thology slides 
were  not available for review; however ,  all had 
documented  invasive disease. 
In 41%, there was  no myomet r ia l  invasion (Fig. 3). In 
43% of the specimens there was  invasion to the inner 
one-third of the myometr ia l  thickness. Cervical 
involvement  was  present  in three patients. In no case 
was  there serosal involvement  of the uterus. 
Grade I 
Ungraded (7%) 
fade 5 (7%) 
Grade 2 (18%) 
Fig. 2. Grade of differentiation, n = 60. 
,ometrial 
Ision (41%) 
Outer I /5  (7%) 
Inner 1/5 (4~ 
zldle I /5 (9%) 
(cervical involvement in three patients) 
Fig. 3. Depth of invasion, n = 60. 
Preoperat ive radiat ion therapy,  usual ly consisting of 
an intracavitary r ad ium or cesium implant,  was  given 
to 15 patients (Table 5). All 15 patients showed 
residual disease in the uterine specimen. Preoperat ive 
radiation was  not given after 1981. Postoperat ive 
radiation therapy was  used in combinat ion with the 
surgery  in nine patients. 
The results of fol low-up are summar ized  in Table 6. 
The median  fol low-up t ime was 7 years. Forty-one out 
Table  5. Adjuvant radiation therapy 
n % 
Preoperative radiation 15 25.0 
Brachytherapy 14 23.3 
External radiation 1 1.7 
Postoperative radiation 9 15.0 
Brachytherapy 4 6.7 
External radiation 2 3.3 
Both 3 5.0 
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Table 6. Outcome* 
n % 
Diagnosis at least 5 years ago 45 100 
Alive NED at 5 years 41 91.1 
Dead NED at 5 years 4 8.9 
DOD at 5 years 0 0 
Diagnosis at least 10 years ago 
Alive NED at 10 years 
Dead NED at 10 years 
No information at 10 years 






*Median follow-up 7 years (1-24 years). NED, no evidence of 
disease; DOD, died of disease. 
of 45 patients were alive at 5 years (91.1%), and 27 out of 
31 (87.1%) at 10 years. Only one patient developed 
recurrence and subsequently died from metastatic 
disease. Briefly, this patient was a 73-year-old white 
female who underwent vaginal hysterectomy because of 
her morbid obesity (250 pounds) in combination with 
hypertension and cardiac disease (aortic stenosis). She 
received a preoperative cesium application. Histologic 
evaluation showed a grade 3 adenosquamous 
carcinoma with 60% myometrial invasion and 
extension to the cervix. The patient then received 40 
Gy of external beam radiation to the whole pelvis. At 5 
years she was without evidence of disease. Six years and 
3 months after the initial surgery she died from lung 
metastases, presumably arising from the endometrial 
cancer. No pelvic recurrence was documented at that 
time. Unfortunately, no autopsy was performed. 
D i s c u s s i o n  
A G O G  study of 621 patients with clinical stage I 
carcinoma of the endometrium clearly demonstrated 
that an appreciable number of early stage patients 
(22%) had disease outside the uterus, with spread to 
pelvic and/or  para-aortic lymph nodes, adnexal 
disease, intraperitoneal spread or positive pelvic 
washings (8). This disease spread cannot be evaluated 
effectively with our present diagnostic tools, such as 
lymphangiography, CT scan or MRI. The most 
accurate assessment is achieved by surgical staging, 
which requires a laparotomy and removal of the 
uterus and the adnexa, pelvic washings and selective 
lymphadenectomy from the pelvic and para-aortic 
area. As endometrial cancer is frequently associated 
with older age, morbid obesity, diabetes meUitus, 
cardiac disease, hypertension, and other risk factors, 
not all patients are candidates for retroperitoneal node 
dissections or even abdominal surgery. 
An alternative approach would be radiation therapy 
alone. However, prognosis is not as good as after 
surgical treatment, as discussed below. 
A hysterectomy using the vaginal approach seems 
to be a suitable alternative, as it is well tolerated with 
few postoperative complications and a low mortali~ 
rate. It is as feasible in obese as in non-obese patients (9). 
Although the older literature seems to support this 
view (2A°), only part of it holds true today, as anesthesia 
techniques and postoperative care have been 
improved significantly. In the past, vaginal 
hysterectomy for endometrial cancer was justified in 
all patients with high surgical risk. Today, a low risk of 
recurrence is also required if this kind of surgery is to 
be performed O1). Although surgical staging provides 
the best estimate of the risk of recurrence, some 
information can be obtained preoperatively. For 
example, the frequency of nodal metastases in the 
para-aortic nodes is significantly related to clinical 
stage, histologic type and grade (8), all of which can be 
determined prior to hysterectomy. 
In our study, all patients had clinical stage I disease. 
However, three patients had cervical involvement not 
detected by fractional D&C. The majority of cases were 
adenocarcinomas, with only one adenosquamous 
carcinoma, the latter having an increased risk of 
developing para-aortic lymph node metastases; and 
86% were either well or moderately differentiated. 
Another classical indication for the vaginal 
approach is pelvic relaxation or prolapse with the 
necessity of an anterior and/or  posterior repair. This 
was done on 10 patients in our series. In a patient with 
endometrial cancer, this is acceptable only if the 
patient belongs to the low-risk group. 
NuUiparity and previous gynecological surgery are 
not absolute contraindications against the vaginal 
approach. With a large uterus which is located high 
in the pelvis, a Schuchardt incision facilitates the 
surgical access. This incision, originally developed by 
Schuchardt for the vaginal radical hysterectomy in 
cervical cancer (12), is an incision similar to a 
mediolateral episiotomy. However, the levator ani 
muscle is almost completely transected. 
Morcellation was done in four patients. MorceUation 
should be avoided if possible, because of the potential 
spread of tumor cells upon opening the endometrial 
cavity. However, none of the four patients in this study 
appeared to be adversely effected by morcellation, as 
none of the patients died of disease. Three out of four 
patients survived more than 5 years. In one patient, the 
follow-up interval was less than 5 years. 
Although adjuvant radiation therapy has not been 
shown to improve significantly survival from 
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endometrial cancer (~3), and most patients with clinical 
stage I disease have a good prognosis anyway, 
radiation was chosen for patients who were 
considered to be at high risk for recurrence because 
of poor tumor differentiation or deep myometrial 
invasion. Until 1981, patients received preoperative 
radiation therapy. Interestingly, all of these patients 
had residual tumor in the uterine specimen at the time 
of vaginal hysterectomy 4-6 weeks later. After 1981, 
preoperative radiation was abandoned in favor of the 
more individualized postoperative radiation therapy. 
A complete long-term follow-up for the 60 patients 
reported in this study is available. Forty-five patients 
were followed for at least 5 years and 31 patients for at 
least 10 years. Four patients had died at 5 years and 
two patients at 10 years of causes other than endo- 
metrial cancer. Only one patient with an advanced 
high-grade adenosquamous carcinoma died of 
recurrence six years after vaginal hysterectomy for 
endometrial cancer. 
The present study is retrospective and no direct 
comparisons are possible between the treatment 
results of vaginal and abdominal surgery or primary 
radiation therapy at the same institution. Several 
studies exist, however, that have made an attempt to 
retrospectively compare abdominal and vaginal 
hysterectomy as treatment for endometrial cancer. In 
those institutions, the indication for vaginal surgery 
was far less restricted than in our study. Scarselli 
e t a / .  (14) compared two consecutive time intervals. 
From 1977 to 1979, the treatment protocol rec- 
ommended vaginal hysterectomy, bilateral salpingo- 
oophorectomy and upper colpectomy. Since 1980, the 
abdominal route (surgical staging including a selective 
pelvic but not para-aortic lymphadenectomy) 
prevailed. There was no significant difference in 
survival between the two groups (87% versus 88%, 
respectively). The rate of severe complications was 
6.8% for abdominal surgery and only 1.1% for vaginal 
surgery. No operative mortality was observed for 
patients operated by the vaginal route, but 2.7% for 
those operated by the abdominal route. 
Candiani et al. (15) compared total abdominal 
hysterectomy with bilateral salpingo-oophorectomy 
with and without selective pelvic lymphadenectomy 
with vaginal hysterectomy and found survival rates of 
73%, 79% and 76%, respectively. Similar results had 
already been reported by the same author in 1978 (16) . 
Bloss et al. (17) reported on their experience with 
vaginal hysterectomy in stage I endometrial cancer of 
31 medically compromised patients. The incidence of 
morbid obesity (87%), hypertension (58%), diabetes 
mellitus (35%) and cardiovascular disease (26%) is 
comparable to the present study. The complication rate 
was also similar (13%). Three-year disease-free 
survival was 100%. 
Carenza et al. (11) treated 160 patients with vaginal 
hysterectomy. Sixty-two per cent were obese. The 5- 
year survival in (clinical) stage I endometrial 
carcinoma was 85.5%, being related to histologic 
grade (grade 1: 95%; grade 2: 86.7%; grade 3: 63.3%). 
The studies mentioned above demonstrate that the 
overall prognosis of clinical stage I endometrial cancer 
is acceptable as long as the uterus is completely 
removed. The survival rates after surgery are still at 
least 15-20% higher than after radiation therapy (2'3"18). 
In conclusion, results of treatment of endometrial 
cancer achieved by vaginal hysterectomy are favorable 
if patients are carefully selected. Therefore, vaginal 
hysterectomy can be an intermediate choice between 
abdominal hysterectomy and primary radiation 
therapy in patients with medical contraindications to 
conventional therapy. Although we consider surgical 
staging as the standard of care for the treatment of 
endometrial cancer, vaginal hysterectomy has a 
definite place in the management of patients with 
good prognostic criteria who are at high operative risk 
for the standard surgical approach. 
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